• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Nagao Hideki

    2/14/25 4:54:40 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNOV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Nagao Hideki

    (Last) (First) (Middle)
    C/O MEDICINOVA, INC.
    4275 EXECUTIVE SQUARE, SUITE 300

    (Street)
    LA JOLLA CA 92037

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MEDICINOVA INC [ MNOV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $1.84 02/12/2025 A 24,500 (1) 02/11/2035 Common Stock 24,500 $0 24,500 D
    Explanation of Responses:
    1. The option vests in four equal installments on May 12, 2025, August 12, 2025, November 12, 2025 and February 12, 2026, subject to continued service with the Company.
    /s/ Yuichi Iwaki, attorney-in-fact 02/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MNOV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MNOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Nagao Hideki

    4 - MEDICINOVA INC (0001226616) (Issuer)

    6/20/25 4:11:47 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lemerond Nicole

    4 - MEDICINOVA INC (0001226616) (Issuer)

    6/20/25 4:11:16 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Beaver Carolyn

    4 - MEDICINOVA INC (0001226616) (Issuer)

    6/20/25 4:10:52 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

    LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that the company has been selected as a winner of the "Contract Research and Development Innovation Award" at the Fifth Annual BioTech Breakthrough Awards. MediciNova earned this recognition for its innovative work advancing MN-166 (ibudilast), the company's lead small molecule drug candidate, currently in development for several neurological diseases, including amyotrophic lateral sclerosis (ALS), one of the fatal neurodegenerative diseases. MN-166 is designed t

    11/6/25 6:00:00 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

    LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the completion of patient enrollment in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (Tipelukast) for the treatment of hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to Type 2 diabetes (T2DM). Patient recruitment is closed. The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to evaluate MN-001(tipelukast). Patients are randomized 1:1 to receive either 500 mg/day of MN-001

    11/4/25 7:00:00 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

    LA JOLLA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces the publication of a new research article in the peer-reviewed Journal of Atherosclerosis and Thrombosis, the official journal of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Disease. The study, titled, "Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis," is the result of a collaboration effort between MediciNova an

    10/30/25 7:00:00 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    SEC Filings

    View All

    SEC Form EFFECT filed by Medicinova Inc

    EFFECT - MEDICINOVA INC (0001226616) (Filer)

    10/1/25 12:15:41 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by Medicinova Inc

    S-1 - MEDICINOVA INC (0001226616) (Filer)

    8/22/25 4:22:25 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Medicinova Inc

    10-Q - MEDICINOVA INC (0001226616) (Filer)

    8/14/25 5:02:14 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on MediciNova with a new price target

    Maxim Group initiated coverage of MediciNova with a rating of Buy and set a new price target of $15.00

    3/16/21 8:15:44 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on MediciNova with a new price target

    Maxim Group initiated coverage of MediciNova with a rating of Buy and set a new price target of $15.00

    3/10/21 7:48:19 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Medicinova Inc (Amendment)

    SC 13D/A - MEDICINOVA INC (0001226616) (Subject)

    7/12/22 12:12:02 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care